Nurix Therapeutics (NASDAQ:NRIX) reported quarterly earnings of $4.73 per share which beat the analyst consensus estimate of $3.98 by 18.84 percent. This is a 559.22 percent increase over losses of $(1.03) per share from the same period last year. The company reported quarterly sales of $673.064 million which beat the analyst consensus estimate of $411.481 million by 63.57 percent. This is a 8.43K percent increase over sales of $7.894 million the same period last year.